Cover Image

PAPERBACK
$63.25



View/Hide Left Panel

REFERENCES

Etzioni R, Ramsey SD, Berry K, Brown M. 2001. The impact of including future medical care costs when estimating the costs attributable to a disease: A colorectal cancer case study. Health Economics. 10(3):245–256.

Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. 2000. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 284(15):1954–1961.

Gold MR, Siebel JE, Russell LB, Weinstein MC, Editors. 1996. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press.

Klabunde CN, Frame PS, Meadow A, Jones E, Nadel M, Vernon SW. 2003. A national survey of primary care physicians’ colorectal cancer screening recommendations and practices. Prev Med. 36(3):352–362.

Mandel JS, Church TR, Ederer F, Bond JH. 1999. Colorectal cancer mortality: Effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 91(5):434–437.

van Ballegooijen M, Habbema JDF, Boer R, Zauber AG, Brown ML. 2003. Report to the Agency for Health Care Research and Quality: A Comparison of the Cost-Effectiveness of Fecal Occult Blood Tests with Different Test Characteristics in the Context of Annual Screening in the Medicare Population.

Whynes DK, Frew EJ, Edwards R, Atkin WS. 2003. Costs of flexible sigmoidoscopy screening for colorectal cancer in the United Kingdom. Int J Technol Assess Health Care. 19(2):384–395.

The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 343(22):1603–1607.

Vijan S, Hwang EW, Hofer TP, Hayward RA. 2001. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med. 111(8):593–601.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement